Full Text
EE613 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Sweden for Adults Aged ≥ 60 Years

Abstract

Authors

L Zarkadoulas L Danielsson K Mårdberg

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×